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Abstract
Although infections are a major concern in patients with primary
systemic vasculitis, actual knowledge about risk factors and
evidence concerning the use of anti-infective prophylaxis from
clinical trials are scarce. The use of high dose glucocorticoids and
cyclophosphamide pose a definite risk for infections. Bacterial
infections are among the most frequent causes of death, with
Staphylococcus aureus being the most common isolate.
Concerning viral infections, cytomegalovirus and varicella-zoster
virus reactivation represent the most frequent complications. The
only prophylactic measure that is widely accepted is
trimethoprim/sulfamethoxazole to avoid Pneumocystis jiroveci
pneumonia in small vessel vasculitis patients with generalised
disease receiving therapy for induction of remission.
Introduction
In patients with small vessel vasculitis (SVV), infectious
complications are at least as often the cause of death as
uncontrolled disease activity. For example, in the recently
published MEPEX-trial about 25% of the patients did not
survive the first year, and most of the deaths were attributable
to overwhelming infectious complications [1]. Despite the
fact that infections substantially contribute to morbidity and
mortality in patients with primary systemic vasculitis (PSV),
data on risk factors and on the burden of specific infectious
agents are scarce. In oncology, recommendations for anti-
infective chemoprophylaxis (AIP) are often derived from
randomised controlled trials evaluating the effectiveness of
the prophylactic intervention itself [2,3]. Such data are widely
missing in PSV.
However, some conclusions might be drawn from therapeutic
trials and cohort studies. For this purpose we analysed 35
such trials [4-37], which were selected according to quality,
patient number and availability of at least some data on
infectious complications (Table 1). Regarding AIP, these data
still have to be interpreted with caution: infection rates are
documented and published with varying degrees of accuracy
depending on the design of the studies. Mild and moderate
infections - that is, those not requiring hospitalisation - appear
to be underestimated, whereas it can be assumed that
deaths due to infections are reported thoroughly.
Furthermore, there are great variations in the use of AIP:
some trials used routine prophylaxis against Pneumocystis
jiroveci pneumonia (PCP; formerly named Pneumocystis
carinii), other fungi and cytomegalovirus (CMV), and others
did not. Most protocols left the use of AIP optional and in
many the actual use was not even recorded, or at least not
reported. Finally, the therapeutic intervention is given
infrequently in sufficient detail; for example, the cumulative
dose of glucocorticoids (GCs) is usually not mentioned.
When thinking about AIP, both the individual risk for the
patient and the evidence for the efficiency and safety of the
prophylactic intervention must be taken into account.
Factors influencing susceptibility to
infections
Because, to date, no PSV trials have used infection as the
primary endpoint, information on possible risk factors can
only be retrieved from adverse event reporting in cohort
studies or therapeutic trials. In Table 1 the rates of infections,
serious infections and fatal infections in different entities and
under distinct medication are summarised. In conjunction
with data from other medical conditions the following conclu-
sions might be drawn.
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.Medication
It is obvious that immunosuppressive medication is a major
risk factor for infections [38]. A high GC dose (often defined
as more than 30 mg per day prednisolone-equivalent),
especially in the form of intravenous methylprednisolone, is a
significant risk factor [1,39]. With respect to common clinical
experience, its importance seems to be underestimated in
clinical trials because, for example, the cumulative GC dose
is not usually stated. In a study on giant cell arteritis (GCA)
solely treated with GCs, 86% of the patients experienced
severe GC-related adverse events, including severe infec-
tions in 31% [40]. Schmidt and colleagues [41] reported a
relative risk of severe infections - that is, infections leading to
hospitalisation - of 2.44 in the first 6 months of GC treatment
in a large GCA trial and increased infection-related mortality.
Rising awareness of GC complications, including infections,
makes GC sparing an increasingly important aim. According
to the European League Against Rheumatism (EULAR) recom-
mendations for conducting clinical trials in PSV, protocols
should be designed to reduce patients’ total exposure to
GCs, which includes recording cumulative GC doses and the
use of GC-sparing drugs like methotrexate (MTX) [42].
Although some trials using cyclophosphamide (Cyc) report
very low rates of infectious complications [17,33], Cyc use in
SVV is associated with higher rates of infections and fatalities
than the use of medium potent immunosuppressants such as
MTX, azathioprine or leflunomide [22,24,26]. Among the
latter no differences concerning rates and types of infections
can be derived from the available data. When analysing infec-
tious complications, it has to been taken into account that
treatment changes over time. For example, the CYCAZAREM-
trial demonstrated that oral Cyc could safely be substituted
by azathioprine after achieving remission, leading to much
lower cumulative Cyc doses [35]. The use of Campath-1H, a
monoclonal antibody to CD52 that leads to lymphocyte
depletion and profound neutropenia, was associated with
high rates of infectious complications, as was expected from
experience with its use in haematology [32]. A clear
association of drugs with specific types of infections, as is
known for tuberculosis (TB) and anti-TNF-α agents, can not
be derived from the still limited data from PSV trials.
Types of vasculitis
As shown in Table 1, there are large differences regarding the
forms of PSV and their infection-related mortality. Infections
and mortality from infectious complications are much more
prevalent in SVV than in large vessel vasculitis. In GCA trials,
mortality ranged from 0 to 0.03 deaths per patient year and
infections caused 0 to 33% of these deaths [4-11]. In SVV
this range was 0 to 0.26 deaths per patient year and
infections were involved in 0 to 100% of the fatal events
[1,17-37].
Interestingly, in most published clinical trials in GCA, PCP
prophylaxis was not used. Despite the fact that high doses of
GCs are a major risk factor for the development of PCP, no
case of PCP has been reported within these trials [4-10]. In
contrast, patients with antineutrophil cytoplasmic antibodies
(ANCA)-associated vasculitis (AAV), especially those with
Wegener’s granulomatosis (WG), are at high risk for PCP
that can not be attributed only to medication [18-29]. There is
evidence that at least some entities within the group of PSV
confer an altered function of the immune defence per se. In
WG, for instance, the granulomatous inflammation of the
upper respiratory tract leads to destruction of the barrier
function of the surfaces, possibly allowing for invasion of
pathogens [43]. It may also be possible that a primary barrier
deficiency not only promotes infections but has a role in the
aetiology of the disease itself [44].
Disease stage and phase of therapy
In PSV, and especially in SVV, the therapeutic approach
usually consists of an induction of remission and a mainte-
nance phase (for review, see [45]). For induction, more
aggressive regimens, including Cyc and higher GC doses,
are utilised. Furthermore, in SVV the selection of drugs
depends on the stage of the disease: in the localised and
early systemic stage - that is, disease without threatened vital
organ function - induction of remission is usually attempted
with medium potent immunosuppressants such as MTX,
whereas in generalised and severe disease - that is, with
threatened vital organ function or organ failure, respectively -
Cyc is used.
In SVV the induction of the remission period is the most
vulnerable phase concerning infections and mortality. From
studies assessing only maintenance of remission, published
mortality rates ranged from 0 to 0.01 deaths per patient year
and infections did not significantly contribute to those
fatalities [18,21,23,27,28,30]. In contrast, trials on induction
of remission in SVV reported mortality rates up to 0.26 per
patient year. In those trials infections were responsible for the
fatal events in up to 100%, and about 50% of deaths, on
average, were due to infections [1,17,20,22,24,26,29,
31-37]. Accordingly, mortality was higher in study popula-
tions with more severe disease. The highest reported rate
was in SVV patients who presented initially with organ (renal)
failure [1]. But even in this population, in which one might
expect a higher contribution of uncontrolled disease to the
death rate, infections are involved in more than 50% of the
fatal outcomes.
Types of infection and options for prophylaxis
Bacterial infections
In PSV trials Staphylococcus aureus is the isolate for which
fatal outcome has been reported most frequently. As
demonstrated in surgical patients and patients on dialysis,
prophylactic topical treatment with mupirocin ointment for
nasal carriers of S. aureus leads to a significant reduction in
the rate of infections with this agent (relative risk 0.55
according to [46]). Especially in WG, the incidence of nasal
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chronic carriage is associated with higher relapse rates [47].
In addition, relapses are often anteceded by infection, mainly
of the upper respiratory tract [48,49]. Furthermore, it is well
documented that trimethoprim/sulfamethoxazole (T/S) treat-
ment reduces the rate of relapse and is able to induce
remission in some WG patients, especially those with localised
disease [28,50]. It is not clear whether this effect is achieved
by its antibiotic or its immunomodulatory properties. Although
its primary end point was relapse rates, the study by
Stegeman and colleagues [28] clearly demonstrated a reduc-
tion in respiratory-tract as well as non-respiratory-tract
infections using T/S in WG patients in remission. This study
can be regarded as the only large scale trial of anti-infective
prophylaxis in vasculitis.
As topical mupirocin does not cause serious adverse events
[46], it is used in some vasculitis centres during the high risk
phase of induction of remission in SVV (seven subsequent
days three times daily per month). One concern, however, is
that with mupirocin there is an increase in infections other
than those due to S. aureus [46]. For reasons of possible
development of resistance as well as compliance problems,
long-term use should be avoided.
Besides topical treatment, systemic antibiotics are another
option for AIP, although they have not been used in PSV
remission induction trials so far. From randomised controlled
trials using, for example, levofloxacine in patients with malig-
nancies during chemotherapy-induced neutropenia (<500
neutrophils per microlitre), it is known that a reduction in the
incidence of neutropenic fever and hospitalisation can be
achieved [2,3]. An effect on mortality has not been
demonstrated and there are concerns regarding the long-
term outcome of such interventions on microbial resistance in
the community. As the treatment of PSV using standard
protocols does not usually lead to prolonged neutropenia and
the effectiveness of chemoprophylaxis with, for example,
levofloxacine with regard to mortality has not been proven in
patients treated with more intense chemotherapy, there is no
standard setting for which the use of systemic antibacterial
prophylaxis can be recommended. Although clear evidence
for its use during induction of remission - apart from PCP-
prophylaxis - is missing, T/S has proven its ability to reduce
bacterial infections in patients with WG [28] and, therefore,
might be considered in high-risk patients.
Other antibiotics, such as levofloxacine, might only be
considered in refractory heavily pre-treated PSV patients
undergoing salvage therapy with drugs known to induce
severe neutropenia - for example, campath-1H.
Pneumocystis jiroveci
The risk of PCP is especially high in patients with SVV
undergoing induction therapy. Without using prophylaxis the
incidence of PCP is up to 20% [26] and many fatalities have
been reported in earlier trials [22,24,26,29]. It has to be
mentioned, however, that the causes of deaths in those
patients were multi-factorial and often due to several infec-
tious agents simultaneously. Furthermore, some of the
mentioned studies referred to the same patient population
[22,24,26]. In a retrospective analysis, Ognibene and
colleagues [51] found an estimated PCP incidence of 6% in
a cohort of 180 WG patients. PCP occurred during induction
of remission. Estimating the risk of PCP during induction of
remission is further complicated as therapeutic strategies
have changed over time, leading to lower cumulative Cyc
doses and less frequent use of high dose intravenous GCs.
Simultaneously, T/S use as PCP prophylaxis has gained
widespread acceptance. Unlike in HIV infection, where a low
CD4 count is the strongest risk factor, such factors are
insufficiently defined in PSV patients. There is evidence that
older age is an independent risk factor [52]. Patients with
WG seem to be at increased risk compared to other AAV or
PSV patients in general. In WG a low lymphocyte count
before and during therapy is associated with PCP [51,52].
Generally speaking, prolonged (>1 month) GC use at doses
>15 to 20 mg per day is the best defined risk factor [53,54].
Other immunosuppressants, especially Cyc, also increase the
risk of PCP [54].
Although, as for all other potential indications for AIP, there
are no clinical trial data on PCP prophylaxis in PSV patients,
there is some evidence for its use in SVV (level B to C):
infection rates were much higher in trials not using prophy-
laxis than in those recommending it [22,26]. Mahr and
colleagues [24] introduced T/S prophylaxis during an
ongoing protocol as a reaction to high rates of PCP and
reported effectiveness. In their analysis, Chung and colleagues
[55] concluded that PCP prophylaxis is cost-effective in WG
patients unless the annual incidence of PCP fell below 0.2%.
According to the EULAR recommendations, T/S prophylaxis
is encouraged in all patients being treated with Cyc [56]. The
British Society for Rheumatology (BSR) formally recom-
mends PCP prophylaxis at a dose of 960 mg T/S thrice
weekly or of 300 mg inhaled pentamidine in all AAV patients
treated with GCs and Cyc [57].
Even though PCP is rare in large vessel vasculitis, the use of
T/S prophylaxis in all PSV patients receiving GCs >15 mg
per day and a GC-sparing immunosuppressant (for example,
MTX) might be considered. As severe adverse event rates
with T/S are generally low and cessation of the medication is
reported in only about 3% of non-HIV-infected patients [58],
generous use seems to be appropriate considering the still
severe prognosis of PCP in this patient population [59].
However, the potential interaction of MTX and T/S has to be
taken into account and strict folate substitution is mandatory.
Furthermore, it has to be stressed that there is only little
evidence from trials to support T/S prophylaxis in patients
receiving medium potency immunosuppression. Its use
should be discussed individually according to local praxis.
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In some centres one criterion to stop PCP prophylaxis is a
GC dose tapered below 15 mg per day and/or the cessation
of Cyc therapy. This praxis is based on the observation that
PCP in non-HIV patients under GC medication occurred
mainly with doses above 15 mg per day [54]. In analogy to
experiences in HIV patients, it has been suggested to
measure CD4 cell counts and to stop prophylaxis when this
value is above 200 per cubic millimetre [60]. However, other
risk factors such as impaired cell functions are under-
estimated by this approach.
Cytomegalovirus
CMV is a herpesvirus that leads to latent infection. Its preva-
lence ranges between 60 and 100%, depending on the
geographic area [61]. CMV reactivation leads to a high
burden of morbidity and mortality in immunocompromised
persons, an interrelation best studied in transplantation
medicine [62]. The spectrum of manifestations ranges from
non-symptomatic infection to life-threatening disease, for
example, pneumonitis. The scale of this problem in rheuma-
tology and especially in PSV patients is insufficiently defined
but appears to be less severe in most cases. In vasculitis
patients leucopenia is the most frequent manifestation.
However, in clinical trials some cases of CMV illness have
been described with a relatively high proportion of fatal
outcomes [20,22,25]. Large scale underreporting must be
assumed, since until recent years reliable detection methods
have been missing and the awareness of this problem
appears to be still low. Mori and colleagues [63] found a high
incidence of CMV reactivation in CMV-seropositive patients
with connective tissue disease undergoing immuno-
suppressive therapy. A recent study by Takizawa and
colleagues [39] suggests that GC use, especially in the form
of pulsed methylprednisolone as well as other immuno-
suppressants, primarily Cyc, are the major risks factors for
CMV reactivation in rheumatic diseases. In PSV, and especially
in WG, CMV reactivation is an important differential diagnosis
if neutropenia occurs.
In solid organ transplant recipients prophylaxis with, for
example, ganciclovir or valganciclovir reduces CMV disease
[64]. If CMV disease occurs in severely compromised
patients with rheumatic diseases, anti-viral therapy might be
without benefit as reported by Takizawa and colleagues [39]
in a cohort of 85 patients. As CMV itself leads to further
immunosuppression, fatal co-infections are promoted [39].
Taken together, these are arguments in favour of anti-viral
prophylaxis in CMV-seropositive PSV patients undergoing
intense immunosuppression. However, as data from clinical
trials are missing, no evidence-based recommendation as to
which patients should be introduced to prophylaxis can be
given. In praxi prophylaxis (valganaciclovir 900 mg once daily)
might be considered only in severely ill PSV patients who
need high dose methylprednisolone pulses or Cyc, especially
if they had experienced earlier CMV reactivations. An
alternative to this, as well as for other latently infected
patients who need intense immunosuppression, is the pre-
emptive approach, which also has been proven to be
effective in organ-transplant recipients [65]. This requires
quantitative monitoring of CMV - for example, by
measurement of early antigen (pp65)-positive cells. Takizawa
and colleagues [39] suggested a threshold of 5.6 pp65
positive cells per 105 polymorphonuclear cells. Measurement
of early antigen is increasingly replaced by quantitative CMV-
PCR, which is currently the method of first choice.
Varicella zoster virus
Varicella zoster virus (VZV) reactivation leads to herpes
zoster (HZ). Whereas age is the most important risk factor
for the development of HZ [66], autoimmune diseases and
especially immunosuppressive therapy with Cyc and GCs
further increases the probability of reactivation [67]. Several
PSV trials report relatively high numbers of VZV reactivation
and HZ [28]. However, underreporting of this usually non-
life-threatening condition is likely. HZ causes substantial
morbidity, especially when post-herpetic neuralgia
develops, which is the case in up to 20% of the elderly
population [68].
Despite these facts, no trial in PSV has included VZV
prophylaxis to our knowledge, although it is feasible and
effective at least in patients receiving haematopoietic stem
cell transplantation using, for example, aciclovir (2 × 800 mg
per day) or valaciclovir [69]. The reason for not administering
VZV prophylaxis in PSV may be the high potential for drug
interactions and adverse events, especially in patients with
renal impairment and the non-life- or organ-threatening nature
of HZ in this population. In general, VZV prophylaxis is not
recommended in PSV patients. It might be considered only in
selected patients who have experienced several VZV
reactivations and have an ongoing need for intense
immunosuppression. More importantly, patients should be
trained to recognise the early signs and symptoms of HZ to
enable the immediate start of anti-viral therapy in the case of
possible HZ.
Vaccination to avoid HZ is available and effective [70]. In the
US it is recommended by the Advisory Committee on
Immunization Practices for all persons older than 60 years
[70] but it is not recommended in patients under immuno-
suppressive medication [71]. Whether patients in remission
from PSV under mild immunosuppression may benefit from
vaccination warrants further investigation.
Fungi
Invasive fungal infections (other than PCP) are rare in PSV.
Risk factors for the development of pulmonary Aspergillus sp.
infections are prolonged episodes of neutropenia and
prolonged use of high-dose GCs [72]. Few cases of invasive
Aspergillus infections and fatalities in PSV have been
reported [13,22,24].
Available online http://arthritis-research.com/content/11/5/253
Page 7 of 11
(page number not for citation purposes)There is generally no indication for the prophylactic use of
systemic anti-mycotics in PSV but aspergillosis should be
considered as a differential diagnosis in patients if fever of
unknown origin does not resolve under a calculated antibiotic
therapy.
In contrast to invasive aspergillosis, Candida infections of
mucosal membranes are a frequent complication of GC
treatment, although leading to invasive candidiasis only very
rarely. Nonetheless, oral candidiasis or candida esophagitis
are painful and might hinder oral nutrition. In critically ill
patients and solid organ transplant recipients prophylaxis
using fluconazole is effective in avoiding invasive candidiasis
[73,74]. Using topical non-absorbable antifungal prophylaxis
in immunocompetent critically ill patients leads also to a
significant reduction in fungal (mainly non-invasive) infections
[75]. According to the BSR, prophylaxis with nystatin, ampho-
tericin or fluconazole should be considered in all AAV patients
receiving high-dose immunosuppressive therapy [57].
In praxi amphotericin suspension in all patients under long
term GC medication with a dose of >15 mg prednisolone per
day can be recommended because it is effective, non-
absorbable and associated, therefore, with very few side
effects. According to a meta-analysis, the non-absorbable
nystatin is not more effective in avoiding fungal colonisation
than placebo and can not be recommended [76]. Additionally,
all patients should be instructed to perform daily self-inspec-
tions of the mouth in order to detect mucosal candidiasis
early.
Mycobacterium tuberculosis
Only a few cases of TB have been reported in PSV trials,
although some of these have been fatal [16]. PSV studies
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Table 2
Possible use of anti-infective chemoprophylaxis in primary systemic vasculitis patients
Infectious agent Prophylactic measure Appropriate clinical situation Level of evidence
Pneumocystis jiroveci Trimethoprim/sulfamethoxazole 960 mg thrice  Should be given to all patients receiving  B to C
weekly. Alternative: monthly aerolized  long term glucocorticoid >15 mg/day and 
pentamidine (300 mg) additional intense immunosuppression
S. aureus Nasal mupirocin ointment three times daily  Might be given to patients with generalised  C
for 7 consecutive days per month SVV who are S. aureus carriers during 
induction of remission
Mycobacterium tuberculosis  Isoniazid 5 mg/kg per day up to 300 mg  If latent tuberculosis is detected and  C
plus pyridoxin (vitamin B6). Alternative:  immunosuppression necessary, especially 
rifampin 10 mg/kg per day up to 600 mg when infliximab is used 
Varicella-zoster virus Aciclovir 2 × 800 mg per day Generally not recommended, but might be  C
considered in very selected cases with 
several reactivations and ongoing need for 
intense immunosuppression
Zoster vaccine Not recommended  C
Cytomegalovirus Valganaciclovir 1 × 900 mg per day Not generally recommended, but might be  C
considered in selected severe cases with 
earlier reactivations and ongoing need for 
intense immunosuppression
Aspergillus sp. For example, posaconazole  Not recommended  C
Candida sp.  Oral amphotericin B suspension,  Should be considered in patients with  C
4 × 1 ml (= 100 mg) per day long term glucocorticoid therapy >15 mg/day
Level of evidence: A = evidence from at least one properly performed randomized controlled trial or meta-analysis of several controlled trials; B =
well-conducted clinical studies, but no randomized clinical trials - evidence may be extensive but essentially descriptive; C = evidence obtained
from expert committee reports or opinions, and/or clinical experience of respected authorities.using TNF-α blocking agents included TB screening as a
reaction to TB reactivations in early rheumatoid arthritis trials.
Therefore, TB reactivation has not been seen in those studies
[9,10,19]. While a general prophylaxis is clearly not indicated,
screening for latent TB should be part of the work-up in PSV
patients. For this purpose a full history, physical examination
and a chest X-ray is recommended by the BSR guidelines
[57], procedures that can be considered to be part of routine
care. If latent TB is detected in a patient planned to start
induction therapy for PVS, we recommend TB prophylaxis.
According to a recent study, rifampin over 4 months might be
safer and associated with better adherence than standard
9-month isoniazid [77]. As long as further trials are
unavailable, we consider isoniazid plus vitamin B supplemen-
tation to be the standard of care, with rifampin being a good
alternative in case of incompatibility.
In some PSV, especially in WG, infliximab is used as salvage
therapy. In such cases screening and prophylaxis for TB
should be performed as recommended for the use of
infliximab in rheumatoid arthritis [78].
Conclusion
Infections significantly contribute to morbidity and mortality in
PSV patients. There are three ways of targeting this problem:
recognising and minimising risk factors, implementing
prophylaxis where appropriate and ensuring early diagnosis
and targeted therapy if infections occur. Although there is an
ongoing need for better definitions of risk factors, from the
available data it is quite clear that prolonged high-dose GC
use is of central significance. Therefore, the reduction of GC
dose must be a major aim in daily praxis as well as in future
studies. To date, the only prophylactic measure that is
recommended by national [57] and international guidelines
[56] is T/S to avoid PCP in SVV patients undergoing intense
immunosuppression. Further prophylaxis might be useful in
specific clinical situations, as summarised in Table 2.
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